## COMMENT



## Postpartum hypertension-The need for definition and classification

Asako Mito<sup>1</sup>

Keywords Postpartum · Pregnancy · Postpartum hypertension

Received: 6 August 2023 / Accepted: 20 August 2023 / Published online: 30 August 2023 © The Author(s), under exclusive licence to The Japanese Society of Hypertension 2023

Postpartum hypertension (PPHTN) is a critical topic because it is associated with some difficulties for both women and newborns, such as postpartum readmission and maternal death. In Japan, of 277 maternal deaths from 2010 to 2015, 30 deaths were due to pregnancy-related hypertension, of which 11 (37%) occurred postpartum [1]. In the United States, 7% of maternal deaths are due to pregnancyrelated hypertension, of which ~70% occur postpartum [2]. PPHTN should be appropriately managed, however there is still much that is not clear; also, there is a lack of evidence for a clear management strategy [3]. Ushida et al. have defined new-onset PPHTN as multiple blood pressure readings of ≥140/90 mmHg at least once between 1 day and 4 weeks postpartum, among normotensive women through antepartum and intrapartum [4]. In the study by Ushida et al., the independent risk factors for new-onset PPHTN [4] were the variables previously reported [5–10], in addition to nulliparous. Similar to previous reports, cesarean section (CS) was a risk factor for new-onset PPHTN, but it is interesting to note that emergency CS was a greater risk factor than scheduled CS [4]. Although the indications for emergency CS were not determined [4], it is possible that some new-onset PPHTN might be an atypical hypertensive disorder of pregnancy (HDP), assuming that some factors that lead to intrauterine hypoxia may be associated with emergency CS, even though HDP was not diagnosed. In addition, most risk factors overlap with the risk factors of HDP. Goel et al. reported that elevated antepartum serum levels of sFlt-1 have been observed in women with de novo PPHTN, suggesting that women with PPHTN may

## Compliance with ethical standards

Conflict of interest The author declares no competing interests.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References

- Petersen EE, Davis NL, Goodman D, Cox S, Mayes N, Johnston E, et al. Vital signs: pregnancy-related deaths, United States, 2011–2015, and strategies for prevention, 13 States, 2013–2017. Morb Mortal Wkly Rep. 2019;68:423–9.
- 2. Katsuragi S, Tanaka H, Hasegawa J, Nakamura M, Kanayama N, Nakata M, et al. Analysis of preventability of hypertensive disorder in pregnancy-related maternal death using the nationwide registration system of maternal deaths in Japan. J Matern Fetal Neonatal Med. 2019;32:3420–6. Maternal Death Exploratory Committee in Japan and Japan Association of Obstetricians and Gynecologists. Maternal Death Exploratory Committee in Japan and Japan Association of Obstetricians and Gynecologists
- Cairns AE, Pealing L, Duffy JMN, Roberts N, Tucker KL, Leeson P, et al. Postpartum management of hypertensive disorders of pregnancy: a systematic review. BMJ Open. 2017;7:e018696.
- Ushida T, Nakamura N, Katsuki S, Mizutani H, Iitani Y, Imai K, et al. New-onset postpartum hypertension in women without a history of hypertensive disorders of pregnancy: a multicenter study in Japan. Hypertens Res. 2023; https://doi.org/10.1038/ s41440-023-01372-14.
- Wen T, Wright JD, Goffman D, D'Alton ME, Attenello FJ, Mack WJ, et al. Hypertensive postpartum admissions among women without a history of hypertension or preeclampsia. Obstet Gynecol. 2019;133:712–9.

represent a group with subclinical or unresolved preeclampsia [9]. However, external factors such as excessive fluid replacement during delivery [7] or postpartum pain and medications that cause vasoconstriction [11] may also be triggers for new-onset PPHTN. Further studies are needed to clarify the definition and classification of PPHTN, including both short-term and long-term prognosis.

Asako Mito mito-a@ncchd.go.jp

Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo 157-8535, Japan

- Parker SE, Ajayi A, Yarrington CD. De novo postpartum hypertension: incidence and risk factors at a safety-net hospital. Hypertension. 2023;80:279–87.
- Redman EK, Hauspurg A, Hubel CA, Roberts JM, Jeyabalan A. Clinical course, associated factors, and blood pressure profile of delayed-onset postpartum preeclampsia. Obstet Gynecol. 2019;134:995–1001.
- 8. Takaoka S, Ishii K, Taguchi T, Kakubari R, Muto H, Mabuchi A, et al. Clinical features and antenatal risk factors for postpartumonset hypertensive disorders. Hypertens Preg. 2016;35:22–31.
- 9. Goel A, Maski MR, Bajracharya S, Wenger JB, Zhang D, Salahuddin S, et al. Epidemiology and mechanisms of de novo and persistent hypertension in the postpartum period. Circulation. 2015;132:1726–33.
- Bigelow CA, Pereira GA, Warmsley A, Cohen J, Getrajdman C, Moshier E, et al. Risk factors for new-onset late postpartum preeclampsia in women without a history of preeclampsia. Am J Obstet Gynecol. 2014;210:338.e1–8.
- Makris A, Thornton C, Hennessy A. Postpartum hypertension and nonsteroidal analgesia. Am J Obstet Gynecol. 2004;190:577–8.